Detalhe da pesquisa
1.
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.
N Engl J Med
; 379(12): 1107-1117, 2018 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30145941
2.
Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial.
Circulation
; 139(3): 366-375, 2019 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30586726
3.
Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.
Lancet
; 392(10161): 2269-2279, 2018 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-30293771
4.
Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.
Am Heart J
; 202: 39-48, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29803985
5.
A mechanistic role for cardiac myocyte apoptosis in heart failure.
J Clin Invest
; 111(10): 1497-504, 2003 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12750399
6.
Opposing effects mediated by the chemokine receptor CXCR2 on myocardial ischemia-reperfusion injury: recruitment of potentially damaging neutrophils and direct myocardial protection.
Circulation
; 108(19): 2387-92, 2003 Nov 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-14568904
7.
Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Galpha(q) transgenic mice.
Circulation
; 108(24): 3036-41, 2003 Dec 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-14638549
8.
The apoptosis inhibitor ARC undergoes ubiquitin-proteasomal-mediated degradation in response to death stimuli: identification of a degradation-resistant mutant.
J Biol Chem
; 282(8): 5522-8, 2007 Feb 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-17142452
9.
Chemokine expression in myocardial ischemia: MIP-2 dependent MCP-1 expression protects cardiomyocytes from cell death.
J Mol Cell Cardiol
; 34(2): 209-21, 2002 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-11851360